4-[(4-aminobutyl)(methyl)amino]-2-{[1-({[1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino}carbonyl)cyclopentyl]methyl}-4-oxobutanoic acid | 849631-53-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-[(4-aminobutyl)(methyl)amino]-2-{[1-({[1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino}carbonyl)cyclopentyl]methyl}-4-oxobutanoic acid
• 英文别名: 4-[4-aminobutyl(methyl)amino]-2-[[1-[[1-(carboxymethyl)-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]carbamoyl]cyclopentyl]methyl]-4-oxobutanoic acid
• CAS: 849631-53-4
• 化学式: C₂₈H₄₀N₄O₇
• 分子量: 544.648
• InChiKey: UAUGBPQYORBALH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  39
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  170
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
  申请人：Hoeltje Dagmar

  公开号：US20050119247A1

  公开（公告）日：2005-06-02

  Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula 1, wherein the substituents R 1 , R 2 , R 3 and R 4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.

  具有中性内肽酶（NEP）和/或人类可溶性内肽酶（hSEP）抑制活性的化合物，其对应于式1，其中取代基R1、R2、R3和R4具有描述中给出的含义，以及包含这些化合物的制药组合物，特别是适用于治疗或抑制心血管疾病、性功能障碍和/或与细胞凋亡相关的不良状况的制药组合物。
• Amidomethyl-Substituted 1-(Carboxyalkyl) Cyclopentyl-Carbonylamino-Benzazepine-N-Acetic Acid Compounds, Process and Intermediate Products for Their Preparation and Pharmaceutical Compositions Containing Them
  申请人：Hoeltje Dagmar

  公开号：US20080085889A1

  公开（公告）日：2008-04-10

  Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R 1 , R 2 , R 3 and R 4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.

  具有中性内肽酶（NEP）和/或人类可溶性内肽酶（hSEP）抑制活性的化合物，其对应于公式I，其中取代基R1、R2、R3和R4具有所述描述中给出的含义，以及含有这些化合物的制药组合物，特别是适用于治疗或抑制心血管疾病、性功能障碍和/或与细胞凋亡相关的不良状况的制药组合物。
• Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
  申请人：Hoeltje Dagmar

  公开号：US20060281732A1

  公开（公告）日：2006-12-14

  Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R 1 , R 2 , R 3 and R 4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.

  具有中性内肽酶（NEP）和/或人类可溶性内肽酶（hSEP）抑制活性的化合物对应于公式I，其中取代基R1，R2，R3和R4具有描述中给出的含义，还包括含有这些化合物的药物组合物，特别是适用于治疗或抑制心血管疾病，性功能障碍和/或与细胞凋亡相关的不良症状的药物组合物。
• AMIDOMETHYL-SUBSTITUTED 1-(CARBOXYALKYL) CYCLOPENTYL-CARBONYLAMINO-BENZAZEPINE-N-ACETIC ACID COMPOUNDS, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Hoeltje Dagmar

  公开号：US20070265244A1

  公开（公告）日：2007-11-15

  Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R 1 , R 2 , R 3 and R 4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.

  具有中性内皮肽酶（NEP）和/或人类可溶性内皮肽酶（hSEP）抑制活性的化合物对应于公式I，其中取代基R1，R2，R3和R4具有描述中给出的含义，以及包含这些化合物的制药组合物，特别是用于治疗或抑制心血管疾病、性功能障碍和/或与细胞凋亡相关的不良情况的制药组合物。
• Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
  申请人：Ziegler Dieter

  公开号：US20050267124A1

  公开（公告）日：2005-12-01

  A combination therapy for the inhibition and/or treatment of sexual dysfunction and/or cardiovascular diseases in humans and other mammals, by administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system, and at least one inhibitor of phosphodiesterase 5.

  一种用于抑制和/或治疗人类和其他哺乳动物性功能障碍和/或心血管疾病的组合疗法，通过施用至少一种中性内肽酶抑制剂、至少一种内源性内皮素生成系统抑制剂和至少一种磷酸二酯酶 5 抑制剂的协同组合。